Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.60 |
| ▸ | CDK2AP1 | O14519 | 6/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706485 | 0.92 | CHEK1 (0.72) | CHEK1CDK2AP1 | |
| SCHEMBL4208380 | 0.92 | CHEK1 (0.72) | CHEK1CDK2AP1 | |
| SCHEMBL4216335 | 0.92 | CHEK1 (0.72) | CHEK1CDK2AP1 | |
| SCHEMBL5000956 | 0.91 | CHEK1 (0.57) | CHEK1CDK2AP1 | |
| SCHEMBL4702699 | 0.88 | CHEK1 (0.54) | CHEK1CDK2AP1JAK3BTK | |
| Trifluoroacetic Acid SCHEMBL4216009 | 0.88 | CHEK1 (0.67) | CHEK1CDK2AP1 | |
| Trifluoroacetic Acid SCHEMBL4211656 | 0.88 | CHEK1 (0.67) | CHEK1CDK2AP1 | |
| SCHEMBL4214970 | 0.88 | CHEK1 (0.57) | CHEK1CDK2AP1JAK3BTKHRH3 | |
| SCHEMBL4705891 | 0.85 | CHEK1 (0.73) | CHEK1CDK2AP1 | |
| SCHEMBL5815671 | 0.84 | CHEK1 (0.53) | CHEK1CDK2AP1JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501814-B2 | Selective androgen receptor modulators | ORION CORPORATION (FI) | 2013-08-06 | — | — | US | disclosed |
| EP-1991523-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ORION CORP (FI) | 2012-08-15 | — | — | EP | disclosed |
| US-20090054525-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2009-02-26 | — | — | US | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1991523-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2008-11-19 | — | — | EP | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007099200-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2007-09-07 | — | — | WO | disclosed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054525-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, FSHR | CHEK1 3825/4885CDK2AP1 3623/4885JAK3 4362/4885 |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885CDK2AP1 2722/4885JAK3 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.